Drug Shortage Report for AMIODARONE HYDROCHLORIDE FOR INJECTION, USP
| Report ID | 194926 |
| Drug Identification Number | 02245248 |
| Brand name | AMIODARONE HYDROCHLORIDE FOR INJECTION, USP |
| Common or Proper name | AMIODARONE HYDROCHLORIDE FOR INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | AMIODARONE HYDROCHLORIDE |
| Strength(s) | 50MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 3 mL |
| ATC code | C01BD |
| ATC description | ANTIARRHYTHMICS, CLASS I AND III |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2023-07-01 |
| Actual start date | 2023-07-01 |
| Estimated end date | 2023-08-28 |
| Actual end date | 2023-07-10 |
| Shortage status | Resolved |
| Updated date | 2023-07-20 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to unforeseen circumstances, we will be encountering a supply interruption on our Amiodarone Hydrochloride for Injection 50 mg/mL MD Vial 3 mL effective July 1, 2023, until August 28, 2023. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2023-07-20 | French | Compare |
| v4 | 2023-07-20 | English | Compare |
| v3 | 2023-07-02 | English | Compare |
| v2 | 2023-06-14 | French | Compare |
| v1 | 2023-06-14 | English | Compare |
Showing 1 to 5 of 5